Modality
ASO
MOA
BCMA ADC
Target
IL-17A
Pathway
RNA Splicing
MDDRCCHuntington's
Development Pipeline
Preclinical
~Jan 2016
→ ~Apr 2017
Phase 1
Jul 2017
→ Feb 2027
Phase 1Current
NCT03080412
2,312 pts·MDD
2017-07→2027-02·Active
2,312 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-02-2611mo awayInterim· MDD
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P1
Active
Catalysts
Interim
2027-02-26 · 11mo away
MDD
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03080412 | Phase 1 | MDD | Active | 2312 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα | |
| RVM-7089 | Revolution Medicines | Phase 3 | IL-17A | |
| Adagrarapivir | Ideaya Bio | Phase 1/2 | IL-17A | |
| Tixatapinarof | Recursion | Approved | FGFR | |
| Terazumab | Recursion | Phase 3 | AHR | |
| Polazanubrutinib | Tango Ther | Phase 1 | IL-17A |